Department of Endocrinology, National Health Commission (NHC) Key Laboratory of Endocrinology (Peking Union Medical College Hospital), Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Front Endocrinol (Lausanne). 2023 Feb 14;13:1015773. doi: 10.3389/fendo.2022.1015773. eCollection 2022.
To analyze the relationship between genotype and phenotype in 21-Hydroxylase deficiency patients harboring P31L variant and the underlying mechanism.
A total of 29 Chinese patients with 21-OHD harboring P31L variant were recruited, and the detailed clinical features of the patients were extracted and analyzed retrospectively. The TA clone combined with sequencing of the region containing the promotor and exon1 of was performed to determine whether the variants in promotor and P31L aligned in cis. We further compared the clinical characteristics of 21-OHD patients between the promoter variant group and no promoter variant group.
Among the 29 patients diagnosed with 21-OHD harboring P31L variant, the incidence of classical simple virilizing form was 62.1%. Thirteen patients owned promoter variants (1 homozygote and 12 heterozygote) and all exhibited SV form. The promoter variants and the P31L variant were located in the same mutant allele as validated by TA cloning and sequencing. There were statistically significant differences in clinical phenotype and 17-OHP level between the patients with and without promoter region variations (<0.05).
There exists high incidence (57.4%) of SV form among the 21-OHD patients harboring P31L variant, and the underlying mechanism is partially due to both the promoter variants and P31L aligning in cis on one allele. Further sequencing of promoter region will provide important hints for the explanation of phenotype in patients harboring P31L.
分析携带 P31L 变异的 21-羟化酶缺乏症患者基因型与表型的关系及其潜在机制。
共纳入 29 例携带 P31L 变异的 21-OHD 患者,回顾性提取并分析患者的详细临床特征。采用 TA 克隆结合启动子和外显子 1 区域测序的方法,确定启动子和 P31L 变异是否在顺式排列。进一步比较启动子变异组和无启动子变异组 21-OHD 患者的临床特征。
29 例诊断为携带 P31L 变异的 21-OHD 患者中,经典单纯男性化型的发生率为 62.1%。13 例患者存在启动子变异(1 例纯合子和 12 例杂合子),均表现为 SV 型。TA 克隆和测序验证了启动子变异和 P31L 变异位于同一突变等位基因上。携带和不携带启动子区变异的患者在临床表型和 17-OHP 水平方面存在显著差异(<0.05)。
携带 P31L 变异的 21-OHD 患者中 SV 型的发生率较高(57.4%),其潜在机制部分归因于启动子变异和 P31L 变异在同一等位基因上顺式排列。进一步对启动子区进行测序将为解释携带 P31L 变异患者的表型提供重要线索。